Buy Rating for Unicycive Therapeutics: Innovative Approach to Hyperphosphatemia Treatment with Oxylanthanum Carbonate

Unicycive Therapeutics (UNCY) has received a new Buy rating, initiated by H.C. Wainwright analyst, Swayampakula Ramakanth.

Swayampakula Ramakanth has given his Buy rating due to a combination of factors surrounding Unicycive Therapeutics’ innovative approach to treating hyperphosphatemia. The company’s lead candidate, oxylanthanum carbonate (OLC), is designed to address the significant unmet need for effective phosphate management in chronic kidney disease patients undergoing dialysis. Current treatments require patients to take a high number of pills daily and often result in gastrointestinal issues, leading to poor compliance.
OLC offers a promising alternative with its novel nanoparticle technology, which allows for a smaller pill size and improved palatability, potentially increasing patient adherence. The drug is under FDA review, with a decision expected by mid-2025, and the company anticipates launching it by the end of that year. With a projected peak revenue of $557 million by 2028 and a strategic commercial plan, Ramakanth sees significant market potential and considers the current valuation of Unicycive Therapeutics attractive for long-term investors.

In another report released on May 21, Benchmark Co. also reiterated a Buy rating on the stock with a $3.00 price target.